RTP Mobile Logo
Submitted by nenadkesic@gmail.com on Thu, 09/26/2013 - 06:04

In these audio proceedings from a closed Think Tank meeting held in June 2013, the invited faculty discuss and debate the current nonprotocol management of renal cell cancer as well as promising research strategies in this area. The roundtable discussion focused on key presentations and papers and actual cases managed in the practices of the faculty where these data sets factored into their decision-making. This content is available in a number of formats for listening on the go with a mobile device or in the office or at home on a computer.
 

Listen to audio excerpts

Track 1: Case discussion: A 63-year-old patient with clear cell metastatic renal cell carcinoma (mRCC) and an asymptomatic primary tumor
Track 2: Local treatment considerations for clear cell mRCC
Track 3: Systematic classification and prediction of complications after cytoreductive nephrectomy in patients with mRCC
Track 4: Assessing rate of progression of residual disease after nephrectomy as a prognostic factor in mRCC
Track 5: Identifying patients with mRCC who are suitable for observation
Track 6: Reliability and limitations of Fuhrman grading in RCC
Track 7: Selection of first-line therapy for patients with clear cell mRCC and an asymptomatic primary tumor
Track 8: Treatment holidays in the management of asymptomatic mRCC
Track 9: Sequencing and side-effect profiles of the VEGF tyrosine kinase inhibitors (TKIs) sunitinib and pazopanib for mRCC
Track 10: Monitoring of liver function tests in patients receiving pazopanib
Track 11: Dose reduction or titration of VEGF TKIs
Track 12: Use of alternate dosing strategies of sunitinib to mitigate toxicity
Track 13: Inactivation of the von Hippel-Lindau gene and rationale for targeting angiogenesis via the VEGF pathway in clear cell RCC
Track 14: Results from RECORD-3: A Phase II trial comparing sequential first-line everolimus and second-line sunitinib to the opposite sequence for mRCC
Track 15: Mechanisms of action and resistance to mTOR inhibitors
Track 16: Use of next-generation sequencing in RCC and other solid tumors
Track 17: Sequencing of VEGF TKIs and mTOR inhibitors
Track 18: Case discussion: A 67-year-old patient with mRCC who receives sunitinib followed by everolimus
Track 19: Risk-benefit analysis of sorafenib versus axitinib
Track 20: Use of temsirolimus in poor-risk RCC
Track 21: Approach to second-line treatment in patients who received first-line VEGF TKI therapy
Track 22: Management of everolimus-associated mucositis and pulmonary toxicity
Track 23: Ongoing clinical trials evaluating bevacizumab/bortezomib in mRCC
Track 24: INTORSECT: Results of a Phase III trial of temsirolimus versus sorafenib for patients with mRCC for whom prior sunitinib therapy had failed
Track 25: Results of a Phase III trial of axitinib versus sorafenib as first-line therapy for mRCC
Track 26: Repeated responses to sequential VEGF-targeted therapies in mRCC
Track 27: Case discussion: A 57-year-old patient with clear cell RCC receives high-dose interleukin-2 (IL-2) after cytoreductive nephrectomy
Track 28: Programmed death ligand 1/3 (PD-L1/PD-L3) tissue expression and response to treatment with IL-2 in RCC
Track 29: Activity of immunotherapeutic agents in patients with RCC and brain metastasis
Track 30: Case discussion: A 63-year-old patient with underlying diabetes and a history of childhood sarcoma presents with multiple pancreatic metastases 9 years after nephrectomy for RCC and experiences major side effects on a series of treatments including sunitinib, everolimus and bevacizumab
Track 31: Management of diabetes and hyperlipidemia in patients receiving everolimus
Track 32: Case discussion: A 75-year-old patient with lung, liver and soft-tissue metastases 4 years after a nephrectomy for clear cell RCC
Track 33: Treatment selection for elderly or frail patients with mRCC
Track 34: Use of high-dose IL-2 in elderly patients with mRCC
Track 35: Results from the Phase III ARISER trial of the anti-G250 antibody girentuximab versus placebo as adjuvant therapy for high-risk clear cell RCC
Track 36: Ongoing adjuvant targeted therapy trials in RCC
Track 37: ASPEN: A Phase II trial of everolimus versus sunitinib in patients with nonclear cell mRCC
Track 38: Case discussion: A 52-year-old patient with nonclear cell mRCC who experiences objective responses to first- and second-line treatment
Track 39: Investigation of anti-PD-1 and anti-PD-L1 antibodies in mRCC and other solid tumors
Track 40: Rationale for the combination of high-dose IL-2 with checkpoint inhibitors for RCC
Track 41: Case discussion: A 64-year-old patient with clear cell RCC and sarcomatoid differentiation receives late-line cabozantinib therapy on a clinical trial
 
FACULTY:
 
Robert A Figlin, MD
Steven Spielberg Family Chair in
Hematology Oncology
Professor of Medicine and
Biomedical Sciences
Director, Division of Hematology Oncology
Deputy Director, Samuel Oschin
Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California
 
Thomas E Hutson, DO, PharmD
Director, GU Oncology Program
Co-Director, GU Center of Excellence Texas Oncology, PA
Charles A Sammons Cancer Center
Baylor University
Medical Center
Professor of Medicine, Texas A&M Health Science Center College of Medicine
Co-Chair of GU Research, US Oncology
Dallas, Texas
 
David F McDermott, MD
Associate Professor of Medicine
Harvard Medical School
Director, Biologic Therapy and Cutaneous Oncology Programs
Beth Israel Deaconess Medical Center
Leader, Kidney Cancer Program
Dana-Farber Harvard Cancer Center
Boston, Massachusetts
 
Robert J Motzer, MD
Medical Oncologist
Memorial Sloan-Kettering Cancer Center
New York, New York
 
David I Quinn, MBBS, PhD
Medical Director
Norris Cancer Hospital and Clinics Leader, Developmental Therapeutics Head, GU Cancer Section
Division of Cancer Medicine and Blood Diseases
USC/Norris Comprehensive Cancer Center
Los Angeles, California
 
Walter Stadler, MD
Fred C Buffett Professor of
Medicine and Surgery
Interim Section Chief, Hematology/Oncology
University of Chicago
Chicago, Illinois
 
 
MODERATOR:
 
Neil Love, MD
Research To Practice
Miami, Florida